The future of
single-domain antibodies

Our euronanomed- “2^2-intratarget” project is financed!

Evry - 3 november

Thank you to the EuroNanoMed III for the grant provided for our project “Nanocarriers to deliver antibodies towards intracellular targets in cancer cells/TAMs at primary/metastatic sites” (2^2-INTRATARGET). Hybrigenics services will select nanobodies (nAbs) against intracellular targets from its patented synthetic library, providing new tools to mediate the intracellular degradation of key oncoproteins.

Back to news

Back to Top